# R-CHOP (lymphoma chemoimmunotherapy)

Source: https://onco.cc/terms/r-chop/  
OnCo record `r-chop` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

R-CHOP is the standard first treatment for diffuse large B-cell lymphoma: rituximab (an antibody against CD20) plus four chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine, prednisone), given every three weeks for six cycles with curative intent. Patients who relapse within a year now go to CAR-T rather than more chemotherapy.

## Summary

CHOP dates from the 1970s; adding rituximab (2002) raised cure rates by about 15 percentage points. Pola-R-CHP swaps vincristine for polatuzumab vedotin and improved progression-free survival (POLARIX); PET-guided shortening to four cycles suffices for low-risk early-stage disease (FLYER). Patients who relapse within a year now go to CAR-T rather than salvage chemotherapy and autologous transplant; bispecific antibodies (glofitamab, epcoritamab) are moving into first line combinations. BR (bendamustine-rituximab) and R-CVP are gentler regimens for indolent lymphomas. 'Chemoimmunotherapy' in lymphoma means antibody plus chemotherapy, not checkpoint inhibitors.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: R-CHOP; R-CHOP21; CHOP-R; Pola-R-CHP; polatuzumab-R-CHP; R-CHOEP; DA-EPOCH-R; R-CVP; bendamustine-rituximab; chemoimmunotherapy; chemo-immunotherapy regimen; R-ICE; R-DHAP; R-GDP

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/R-CHOP
- Wikipedia: https://en.wikipedia.org/wiki/R-CHOP

## Connected records

- terms: [Anthracyclines (doxorubicin, epirubicin)](https://onco.cc/terms/anthracycline/), [CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it](https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/), [Deauville score and PET-adapted therapy](https://onco.cc/terms/deauville/), [Regimen and cycles](https://onco.cc/terms/chemotherapy-regimen/), [Salvage therapy](https://onco.cc/terms/salvage-therapy/), [The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest](https://onco.cc/terms/lymphoma-tx-regimen-alphabet/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [EBV-positive diffuse large B-cell lymphoma](https://onco.cc/cancers/ebv-positive-dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)](https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/), [Intravascular large B-cell lymphoma](https://onco.cc/cancers/intravascular-large-b-cell-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Mediastinal grey zone lymphoma](https://onco.cc/cancers/mediastinal-grey-zone-lymphoma/), [Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)](https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/), [Richter transformation of chronic lymphocytic leukaemia](https://onco.cc/cancers/richter-transformation-cll/), [T-cell/histiocyte-rich large B-cell lymphoma](https://onco.cc/cancers/t-cell-histiocyte-rich-large-b-cell-lymphoma/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Rituximab](https://onco.cc/drugs/rituximab/), [Vincristine](https://onco.cc/drugs/vincristine/)
- trials: [Alliance/CALGB 50303](https://onco.cc/trials/calgb-50303/), [ARCHED](https://onco.cc/trials/arched/), [ENRICH](https://onco.cc/trials/enrich/), [FLYER](https://onco.cc/trials/flyer/), [GOYA](https://onco.cc/trials/goya/), [IELSG37](https://onco.cc/trials/ielsg37/), [Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma](https://onco.cc/trials/mosun-len-mzl/), [POLAR BEAR](https://onco.cc/trials/polar-bear/), [REMARC](https://onco.cc/trials/remarc/)
- key papers: [Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303](https://onco.cc/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/), [Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study](https://onco.cc/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/), [Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER)](https://onco.cc/key-papers/paper-flyer-four-vs-six-cycles-r-chop-lancet-2019/), [Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial](https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/), [Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP](https://onco.cc/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/), [Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/), [Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)](https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/r-chop.json